Member Info for Nolupus

Draye ,

I am well aware of what the RNS states but there are 2 distinct parts to the trial …I stick to my estimation but everyone to their own …

Draye ,

It’s quite impossible to give any guidance on P3 readouts at this stage , as we don’t even have a start date for the P2 part … 2024 maybe for the P2 part but probably late 2025/ early 2026 for the P3 results , imo but we will have to wait and see the protocol before being more precise….

Best of luck to the patient

Cauldstream7,

My point was that there are 2 approved drugs on the market already and not just 1 …
Like all drugs , they have potential side effects and therefore are not suitable for some Lupus sufferers.
There is always room for Lupuzor on the market but it is still years away from any potential approval so no point talking about ´ market potential ´ until /when /if we cross that line , imo

Maidit308,

Please get your facts right before posting a lot of hype …

All you have to do is google Saphnelo….

Usually means that a cash raise is on the cards when we get reports but wtfdik

The SP is not reacting as it should at the moment either

I wonder what is going on in the background ?

Lordloadsoflolly,

I would imagine that the small financial upfront would be enough to pay some PhD student in Bordeaux for a year ( mid 5 digit sum ) imo bwtfdik

Anyway , it’s an interesting collaboration that could have been milked more by IMM if they so wished, imo. ( that is an anomaly and should be noted :-)

Lordloadsoflolly,

Whilst I agree to a lot of what you are saying , there are multiple positives in this RNS , imo

1). I appreciate the tone of this RNS which is factual and to the point ( No blatant ramping from Tim and they specified that it was a small financial upfront )

2). The collaboration is with Top class teams ( French Govt backed Orano and we can also highlight the CNRS behind the team in Lyon …

Whilst the collaboration may or not yield positive results , it’s good to see that IMM has still got a lot of backing in France !

But everyone to their own points of view as per usual

Trek,

We all know that IQAI are a software company that has no experience to do a clinical trial in cancer patients . This comes across as ´ window dressing’ to me … come and buy me out big pharma , seems to be Trevor’s objective, but in what timeframe ?

Only the ST holders are focused on the SP …

The SP does not reflect the potential is all one can say at the moment, imo

But things can change very quickly or very slowly , one just has to follow one’s convictions :-)

Radar,

Hope is for those that don’t have convictions after doing some solid research …
If one is relying on Hope to make money on the markets well chances are one will lose their shirts ..
Research =convictions =patience , gives one better odds , imo

Lot’s to look forward to in the months ahead , just needs a bit of patience …imo

Scored,

Patience is a virtue :-)

It all depends on which Tim you are talking about :-)

Don’t forget TIM Franklin !

I hope he is very active as there is a lot of work to be done , imo

Wonder why a security / X-ray company has taken a stake here ?

Trek,

You should have told us , so we could buy some before you :-)

Draye,

As far as I know , that program was discontinued a long time ago …

If you are relying on major revenue from distributing Avion’s products , you should read up on the initial project , which is on a named person’s basis ….( to begin with ) …

Link

https://www.proactiveinvestors.co.uk/companies/news/1000014/immupharma-may-broaden-its-collaboration-with-us-partner-avion-1000014.html

Could we get an update on the CIPD program next ?

It could be possible that Tim pulls this rabbit from his hat , and hopefully with a European backer this time around ??

Let’s wait and see ….

Ps extract

In addition to lupus, there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy ("CIDP")

5 rings ,

What is positive is that Avion and Immupharma have agreed on the clinical way forward . What could have been excellent is that we could have been told that Avion are funding this …

The only financial comment was this ..
´It is also expected to be less costly overall´

Why tell us this , and only this ?
If Avion was footing the full bill , do you think we would be concerned about the cost ??

Anyway , let’s wait for further details on the funding side .

Whilst the RNS is a positive one albeit incomplete, why are we now red ?
Unbelievable….

Just goes to show what shenanigans go on